Supreme Court Should Ban Mail-Order Abortions, Protect Women From Dangerous Abortion Pills
Life News
Source: lifenews.com
📰 Risk Evaluation News
Page 11 - Risk Evaluation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Risk Evaluation. Real-time updates on events, politics, business and more.
FDA approves Buprenorphine treatment option for opioid addiction
EYEWITNESS NEWS (WBRE/WYOU) — The U.S. Food and Drug Administration (FDA) approved a Buprenorphine treatment option for opioid addiction. According to the FDA, Brixadi is an extended-release injection for use under the skin (subcutaneously) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two forms, a weekly injection for patients who […]
Robertm Califf Braeburn Inc Mental Health Services Administration Drug Administration Prevention Framework Substance Abuse
Source: yahoo.com
Analyses of Kite's Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas -December 11, 2023 at 09:01 pm EST
– ZUMA-1 Post-Hoc Analysis Shows Five-Year Lymphoma-Related Event-Free Survival in a Substantial Proportion of Patients with Refractory Large B-cell Lymphoma – – Four-Year Follow-up from...
Source: marketscreener.com
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of The
At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimensResponses were significantly improved with Abecma and continued to deepen over time with a complete response rate of 44% v...
United Kingdom United States Paula Rodriguez Otero Sergio Giralt Hemophagocytic Lymphohistiocytosis Bristol Myers Squibb
Source: pharmiweb.com
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 11, 2023--
United States United Kingdom Hemophagocytic Lymphohistiocytosis Elizabeth Pingpank Bristol Myers Squibb Sergio Giralt
Source: eagletribune.com
Long-Term Data for Kite's Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma -December 11, 2023 at 05:46 pm EST
– First Ever Prospective Phase 2 Study to Evaluate CAR T-Cell Therapy as First-Line Therapy Reads Out Three-Year Follow-Up Analysis – – At Median Follow-Up of 40.9 Months, Patients Treated...
Source: marketscreener.com
Long-Term Data for Kite's Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.
Source: financialpost.com
New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
/PRNewswire/ -- Johnson & Johnson announced today an analysis from the Phase 1/2 MonumenTAL-1 study of TALVEY™ (talquetamab-tgvs) in patients with relapsed or...
United States San Francisco Christie Corbett Satu Glawe Christoph Heuck American Society Of Hematology
Source: prnewswire.com
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
SOMERSET, N.J.--(BUSINESS WIRE)--Dec 11, 2023--
Source: eagletribune.com